Trial Profile
A retrospective study investigating efficacy of Crizotinib in patients with advanced lung adenocarcinoma and aROS1 rearrangement.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2015
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- Acronyms EUROS1
- 29 Dec 2015 New trial record